TAS-120

futibatinib · Taiho Oncology, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for TAS-120, covering 2024-03-20 to 2026-03-10. Get the full timeline:

Most recent: Clinical Trial Update: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements